跳至主要内容
临床试验/ACTRN12613001164785
ACTRN12613001164785尚未招募未知

In Maori and Pacific Island children with Non-Cystic Fibrosis Bronchiectasis, will measurement of CD62 Ligand shedding detect defects of the innate immune system?

Starship Clinical Immunology and Allergy Department0 个研究点目标入组 100 人开始时间: 2013年10月21日最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
o limit 至 15 Years(—)
性别
All

入选标准

  • Bronchiectasis group: <15 years old at time of enrolment, Maori or Pacifica, confirmed bronchiectasis on HRCT scan, clinical diagnosis by respiratory physician, consent to study.
  • Healthy control group: <15 years old at time of enrolment, Maori or Pacifica, consent to study.

排除标准

  • Bronchiectasis group: Cystic fibrosis not excluded as diagnosis, known primary immunodeficiency, primary ciliary dyskinesia, non-consent to study.
  • Healthy control group: Infectious comorbidities, history of recurrent infections or Rheumatic Fever, non-consent

研究者

发起方
Starship Clinical Immunology and Allergy Department

相似试验